Non-steroidal anti-inflammatory drugs an overview of cardiovascular risks

Three trials (n = 918) compared the effects of NSAIDs to those of placebo on pain reduction. The pooled mean difference showed comparable pain reduction (visual analogue scale, 0 to 100) in the NSAIDs and placebo groups ( MD -, 95% CI - to ). Heterogeneity was high (I 2 = 82%), and the quality of the evidence was very low. When we excluded one trial with a short follow-up of eight hours, the mean difference further decreased ( MD -, 95% CI - to ). Three trials (n = 753) compared NSAIDs to placebo regarding global improvement. We found low - quality evidence that NSAIDs are more effective than placebo with a risk ratio of (95% CI to ). One trial (n = 214) studied the effect of NSAIDs on disability, finding very low - quality evidence that NSAIDs are no more effective than placebo on disability. Four trials (n = 967) comparing NSAIDs to placebo reported adverse effects , with low - quality evidence that the risk for adverse effects is higher in the NSAID group than in the placebo group ( RR , 95% CI to ). The adverse effects reported in this review are consistent with those previously reported in the literature.

Non-steroidal anti-inflammatory drugs an overview of cardiovascular risks

non-steroidal anti-inflammatory drugs an overview of cardiovascular risks

Media:

non-steroidal anti-inflammatory drugs an overview of cardiovascular risksnon-steroidal anti-inflammatory drugs an overview of cardiovascular risksnon-steroidal anti-inflammatory drugs an overview of cardiovascular risksnon-steroidal anti-inflammatory drugs an overview of cardiovascular risksnon-steroidal anti-inflammatory drugs an overview of cardiovascular risks

http://buy-steroids.org